- Home
- NTLA vs EVV Comparison
NTLA vs EVV Comparison
Compare NTLA & EVV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTLA
- EVV
- Stock Information
- Founded
- NTLA 2014
- EVV 2003
- Country
- NTLA United States
- EVV United States
- Employees
- NTLA N/A
- EVV N/A
- Industry
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- EVV Finance/Investors Services
- Sector
- NTLA Health Care
- EVV Finance
- Exchange
- NTLA Nasdaq
- EVV Nasdaq
- Market Cap
- NTLA 1.2B
- EVV 1.2B
- IPO Year
- NTLA 2016
- EVV N/A
- Fundamental
- Price
- NTLA $12.06
- EVV $10.39
- Analyst Decision
- NTLA Buy
- EVV
- Analyst Count
- NTLA 20
- EVV 0
- Target Price
- NTLA $32.30
- EVV N/A
- AVG Volume (30 Days)
- NTLA 4.2M
- EVV 323.7K
- Earning Date
- NTLA 08-07-2025
- EVV 01-01-0001
- Dividend Yield
- NTLA N/A
- EVV 9.66%
- EPS Growth
- NTLA N/A
- EVV N/A
- EPS
- NTLA N/A
- EVV N/A
- Revenue
- NTLA $52,857,000.00
- EVV N/A
- Revenue This Year
- NTLA $8.32
- EVV N/A
- Revenue Next Year
- NTLA N/A
- EVV N/A
- P/E Ratio
- NTLA N/A
- EVV N/A
- Revenue Growth
- NTLA 14.99
- EVV N/A
- 52 Week Low
- NTLA $5.90
- EVV $8.52
- 52 Week High
- NTLA $23.76
- EVV $10.07
- Technical
- Relative Strength Index (RSI)
- NTLA 60.10
- EVV 67.14
- Support Level
- NTLA $11.29
- EVV $10.21
- Resistance Level
- NTLA $12.46
- EVV $10.36
- Average True Range (ATR)
- NTLA 0.56
- EVV 0.07
- MACD
- NTLA 0.12
- EVV 0.02
- Stochastic Oscillator
- NTLA 84.85
- EVV 99.09
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
About EVV Eaton Vance Limited Duration Income Fund of Beneficial Interest
Eaton Vance Ltd Duration Income Fund is a diversified closed-end management investment company. The company's investment objective is to provide a high level of current income. The Fund also seeks capital appreciation. The Fund invests predominantly in Senior Floating-Rate Loans, Debt Obligations, Equity Securities, Derivatives as well as Foreign Securities and Currencies. The Fund invests in various industries, including aerospace and defense, automotive, building and development, healthcare, and leisure, among others.